Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.

Mani Foroohar, M.D., of Leerink Partners, says that the decision reflects “how sharp the departure has been between the prior ...

Stock investors face tough odds, with only 26% outperforming the Nifty 500 TRI amid shrinking market breadth and rising valuations.

Former FDA chief Scott Gottlieb warns Hims & Hers could face DOJ action for an unapproved oral GLP-1 semaglutide copy.

Some pharmaceutical companies not targeted by President Donald Trump for agreements to lower their U. drug pricing are looking to craft their own deals in an attempt to avoid potentially onerous ...

WUHC ’s annual event is the nation’s largest undergraduate healthcare conference. The day included four panels on topics of ...

Bristol Myers Squibb (NYSE: BMY; BMS) beat analyst consensus forecasts by reporting higher than expected numbers for total revenue and its “growth” portfolio of drugs on which BMS is counting on for ...

A year of significant policy change at the FDA brought momentum and scrutiny into the new year. As 2026 gets underway, biopharma companies are responding to sweeping vaccine changes while concerns ...

Sales have been falling within the company’s cell-therapy portfolio.

The US Food and Drug Administration's (FDA’s) Center for Biologics Evaluation and Research (CBER) is refusing to review Moderna’s application for approval of a new flu vaccine. The decision comes ...

Brian Chesky, Airbnb co-founder and CEO, joins 'Squawk on the Street' to discuss Airbnb's latest earnings results, 2026 ...

Scott McNealy, former Sun Microsystems CEO and LittleHorse chairman, joins 'Squawk Box' to discuss Big Tech's investments in ...